Evidence map›Paper›PMID 35740068›Full record

ArticleAntioxidants (Basel, Switzerland)2022

HO-1 Limits the Efficacy of Vemurafenib/PLX4032 in BRAF

Anna Lisa Furfaro, Giulia Loi, Caterina Ivaldo, Mario Passalacqua, Gabriella Pietra, Giovanni Enrico Mann, Mariapaola Nitti

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Anna Lisa FurfaroDepartment of Experimental Medicine, University of Genoa, Via L.B. Alberti 2, 16132 Genova, Italy.ORCID 0000-0003-3538-2056
Giulia LoiDepartment of Experimental Medicine, University of Genoa, Via L.B. Alberti 2, 16132 Genova, Italy.
Caterina IvaldoDepartment of Experimental Medicine, University of Genoa, Via L.B. Alberti 2, 16132 Genova, Italy.
Mario PassalacquaDepartment of Experimental Medicine, University of Genoa, Via L.B. Alberti 2, 16132 Genova, Italy.ORCID 0000-0003-2779-6259
Gabriella PietraDepartment of Experimental Medicine, University of Genoa, Via L.B. Alberti 2, 16132 Genova, Italy.
Giovanni Enrico MannKing's British Heart Foundation Centre of Research Excellence, School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, 150 Stamford Street, London SE1 9NH, UK.
Mariapaola NittiDepartment of Experimental Medicine, University of Genoa, Via L.B. Alberti 2, 16132 Genova, Italy.
University of Genoa · ITKing's College London · GBOspedale Policlinico San Martino · IT

Funding

British Heart Foundation FS/16/67/32548COST action BenBedPhar CA20121Heart Research UK RG2673Italian Ministry of Health RF-2016-02362288
6 · The paper itself

Abstract

Induction of heme oxygenase 1 (HO-1) favors immune-escape in BRAF

Indexed as

HO-1hypoxiamelanomaNK ligandsNRF2oxygen tensionphysiological normoxiaresponse and/or resistance to therapytarget therapy

Identifiers

PMID35740068
PMCPMC9219655
OpenAlexW4282925927

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.